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A set of triterpenoids with different grades of oxidation in the lupane skeleton were 
prepared and evaluated as cholinesterase inhibitors. Allylic oxidation with selenium oxide and 
Jones’s oxidation were employed to obtain mono-, di- and tri-oxolupanes, starting from 
calenduladiol (1) and lupeol (3). All the derivatives showed a selective inhibition of 
butyrylcholinesterase over acetylcholinesterase (BChE vs. AChE). A kinetic study proved that 
compounds 2 and 9, the more potent inhibitors of the series, act as competitive inhibitors. 
Molecular modeling was used to understand their interaction with BChE, the role of carbonyl at 
C-16 and the selectivity towards this enzyme over AChE. These results indicate that oxidation 
at C-16 of the lupane skeleton is a key transformation in order to improve the cholinesterase 
inhibition of these compounds. 
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1. Introduction 
Cholinesterase inhibition is the most accepted therapeutic strategy for the treatment of 
Alzheimer’s disease (AD), a progressive neurodegenerative disorder that affects the elderly 
population and causes memory impairment and cognitive deficit [1–3]. The inhibition of 




acetylcholine, can alleviate AD symptoms by improving cholinergic functions in AD patients. 
In the healthy brain, the enzyme butyrylcholinesterase (BChE) is also involved in the metabolic 
degradation of acetylcholine, although the cholinesterase activity of AChE is much higher than 
that of BChE [4, 5]. In AD patients, the AChE/BChE ratio depends on the brain region and the 
stage of the disease progression. BChE can compensate AChE activity when its levels are 
decreased. Since BChE activity increases as AD progresses, this enzyme may also play an 
important role in cholinergic dysfunction, particularly at the later stages of AD [6]. 
As part of our research program focused on the discovery of new cholinesterase 
inhibitors, we recently reported the synthesis of several analogs of calenduladiol (lup-20(29)-en-
3β,16β-diol, 1) and the selective BChE inhibition observed for 3,16-dioxolup-20(29)-en-30-al 
(2) (Figure 1) [7]. Taking into account those results, in this work we further investigated the role 
of the oxidation of the lupane skeleton in the BChE inhibition. For that purpose, we chose two 
natural compounds, lupanes 1 and 3, as starting material and carried out chemical 
transformations that provided a set of lupane derivatives with selective oxidation at C-3, C-16, 
and/or C-30. All the derivatives were evaluated as cholinesterase inhibitors, and a kinetic study 
was performed for the two more potent BChE inhibitors. Also, the key binding interactions 
between these compounds and BChE was studied through docking modelization. 
 
 
Figure 1. Structure of calenduladiol (1), 3,16-dioxolup-20(29)-en-30-al (2) and lupeol (3). 
 





Our previous findings revealed that trioxolupane (2) may provide a useful template for 
the development of new lupane derivatives with improved and selective BChE inhibition [7]. A 
set of 11 lupane derivatives were prepared by different oxidation strategies in order to obtain 
analogs selectively oxidized at the same three positions as on compound 2, that is, positions 3, 
16, and 30 of the lupane skeleton. Cholinesterase inhibition was determined for each compound 
and the results were analyzed with the aid of molecular modeling. 
Taking into account our previous results, we designed a strategy to obtain a set of 
compounds with different grades of oxidation in the lupane skeleton, starting from two natural 
triterpenes, calenduladiol (1) and lupeol (3), both isolated for this purpose from Chuquiraga 
erinacea subsp erinacea (Asteraceae) following a procedure already reported [8]. Allylic 
oxidation with selenium oxide and Jones’s oxidation were employed to obtain mono-, di- and 
tri-oxolupanes that would allow us to determine which carbonyl group is necessary for enzyme 
inhibition. In order to analyze the role of the hydroxyl/carbonyl groups at C-3, C-16, and C-30, 
we have carried out the transformations shown in Scheme 1 and Scheme 2.  
Initially, lupeol (3) was treated with Jones reagent to obtain lupenone (4) (lup-20(29)-
en-3-one) with excellent yield (93%). Starting also from 3, allylic oxidation at C-30 led us to 
α,β-unsatured aldehyde 5 (3β-hydroxy-lup-20(29)-en-30-al). Then, oxidation of compound 5 
with Jones reagent rendered 3,30-dioxolupane 6 (3-oxo-lup-20(29)-en-30-al) (Scheme 1).  
The alternative route for preparing compound 6 by treating intermediate 4 with 
selenium oxide was discarded on the basis of the results reported by Gutierrez-Nicolás et al. in 
the allylic oxidation of lupenone, where this reaction also rendered the α,β-unsaturated ketone at 
ring A together with the desired oxidation of C-30 [9]. 
Compounds 4, 5, and 6 were purified by column chromatography and identified by 
comparison of their spectroscopic data with those reported in the literature. Ketone 4 has been 
found as a natural compound in different plant species, and was also obtained by synthesis and 
used in further preparation of other synthetic analogs [10–15]. Compound 6 was identified by 
Mutai et al as a secondary metabolite found in Acacia mellifera [11]. Spectroscopic data of 5 






Scheme 1. Preparation of compounds 4–6. Reagents and conditions: (a) Jones reagent, acetone; 
(b) SeO2, EtOH, reflux. 
 
Following the same strategy but starting from calenduladiol (1), we were able to prepare 
compounds 7 (3β,16β-dihydroxy-lup-20(29)-en-30-al) and 2 (3,16-dioxo-lup-20(29)-en-30-al) 
(Scheme 2). The oxidation of 1 directly with Jones reagent led us to compound 8 (3,16-dioxo-
lup-20(29)-ene) as the major product, together with the partially oxidized analogs, 9 (3β-
hydroxy-lup-20(29)-en-16-one) and 10 (16β-hydroxy-lup-20(29)-en-3-one), in 42:24:34 ratio, 
respectively (Scheme 2). Compounds 8–10 were separated by column chromatography. Then, 
allylic oxidation of compound 9 rendered compound 11 (3β-hydroxy-16-oxo-lup-20(29)-en-30-
al, 47.2% yield), while compounds 12 (16β-hydroxy-3-oxo-lup-20(29)-en-30-al, 13.7% yield) 
and 13 (16β-hydroxy-3-oxo-lup-1,20(29)-dien-30-al, 18.7 % yield) were obtained from 10 at the 





Scheme 2. Preparation of compounds 2, 7–13. Reagents and conditions: (a) Jones reagent, 
acetone; (b) SeO2, EtOH, reflux. 
 
The synthesis of 11 and 12 starting from compound 7 was theoretically possible. When 
we tried to do so by careful addition of Jones reagent onto a cooled solution of 7, the TLC 
showed the presence of three compounds. The chromatographic separation of the reaction crude 
rendered starting compound 7 as the major product, together with a mixture of 11 and 12 that 
could not be separated. These results prompted us to try the alternative route described 
previously (Scheme 2), even though we could expect the formation of some elimination product 
in ring A [9]. Taking into account that ketones 9 and 10 were obtained as minor byproducts in 
the synthesis of compound 8, reaction conditions were optimized in order to promote the 
formation of those products instead of 8. After careful column chromatography we were able to 
obtain ketones 9 and 10 in adequate amounts to approach the next step, the allylic oxidation of 
each one separately. Thus, we were able to obtain compounds 11 and 12, both with the α,β-
unsatured aldehyde moiety in the side chain, but with selective oxidation of C-3 or C-16. As it 
was expected, compound 13 was also obtained, together with compound 12, but their separation 
was successfully achieved by column chromatography. 
Lupanes 2, 7, and 8 were identified by comparison of their spectroscopic data with those 








reported for the natural triterpenoid isolated from Acacia cedilloi (Fabaceae), known as resinone 
[17]. Compounds 9, 11, 12, and 13 are, on the other hand, new lupane derivatives and were 
identified with the aid of NMR spectroscopy and MS spectrometry. Assignments of all carbon 
and relevant proton signals were achieved with the aid of mono- and bi-dimensional NMR 
experiments and comparison with NMR data of the known analogs and/or starting triterpenoids 
[7, 9, 17, 18].  
 
2.2 Cholinesterase inhibition 
The AChE and BChE inhibitory activity of compounds 4–13 was evaluated and 
compared to that of natural triterpenoids 1 and 3, and compound 2. AChE and BChE activities 
were measured in vitro by the spectrophotometric method developed by Ellman with slight 
modifications with tacrine as the reference inhibitor [19].  
In a preliminary assay the inhibition percentage at a fixed concentration was determined 
for all the derivatives. Compounds 1–13 acted like weak AChE inhibitors with low inhibition 
percentages. On the other hand, compounds 2, 8, 9 and 11 showed better BChE inhibition than 1 
under the same experimental conditions (Table 1). The concentration required for 50% BChE 
inhibition (IC50) was then determined for these compounds. The results for cholinesterase 
inhibition are summarized in Table 1. 
 









         IC50 (μM) 
1
 b
 8.1 ± 0.2 42.0 ± 0.8 >200 
2
 b
 21.7 ± 1.2 86.5 ± 2.7 21.5 ± 1.2 
3 21.3 ± 2.7 31.0 ± 2.2 >200 
4 8.8 ± 1.2 10.2 ± 1.4 - 
5 5.7 ± 0.4 3.2 ± 1.0 - 
6 n.i. 
c 28.9 ± 3.1 - 
7
 b
 43.5 ± 1.1 42.0 ± 4.4 >200 
8 6.4 ± 0.3 61.4 ± 0.5 154.6 ± 2.3 




10 12.6 ± 1.5 43.5 ± 0.9 >200 
11 29.7 ± 0.8 > 100 76.8 ± 0.3 
12 n.i.
 c 35.3 >200 
13 n.i.
 c 44.6 ± 0.6 >200 
tacrine d - - 0.004 ± 0.001 
                          a at 200 μM, b From ref. 7, c n.i. : no inhibition detected, d reference inhibitor. 
 
The best activity was observed for compound 2, with three carbonyl groups in positions 
3, 16 and 30, followed by compound 9 (3β-hydroxy-lup-20(29)-en-16-one). All the compounds 
bearing a 16-keto group were more effective inhibitors than the 16β-hydroxy analogs (9 vs. 1, 
11 vs. 7, 8 vs. 10, 2 vs. 12,) or the unsubstituted lupanes (9 vs. 3, 11 vs. 5, 8 vs. 4, 2 vs. 6,) 
(Figure 2).  
 
Figure 2. BChE inhibitors grouped according their substitution at C-16. 
 
2.3 Kinetic characterization of BChE inhibition 
Carbonyl compounds 2 and 9, identified as the more effective BChE inhibitors of the 
series, were chosen for the determination of the inhibitor type kinetic study. Enzyme activity 
was evaluated at different fixed inhibitor concentrations and increasing substrate concentrations 
and, the data obtained was used to elucidate the enzyme inhibition mechanism. The results are 
illustrated in the form of Lineweaver–Burk plots (Figure 3). The double-reciprocal plots showed 
that the inhibitors have not effect on Vmax, but increase Km. The pattern of straight lines with 




inhibitor. Both 2 and 9, interfere with the substrate binding to the enzyme. The analysis of these 
data with GraphPad Prism 5 showed a good fit with the competitive type inhibition. Estimated 
Ki were 51.16 μM for 9 and 32.70 μM for 2. This kinetic study indicates that both 2 and 9 have 
affinity for the active site of the enzyme and compete with the substrate. 
 
 
Figure 3. Lineweaver–Burk plots of the inhibition of BChE by compound 2 (A) and 9 (B) with 
















































2.4 Molecular modeling study 
In order to understand the selective BChE inhibition of compounds 2 and 9 over AChE 
inhibition, molecular docking studies were performed with both cholinesterases to compare 
their affinities. Owing to the large volume of the BChE active-site gorge (200 Å
3
 bigger than 
that of the AChE gorge), one or more molecules of water can be placed there in order to interact 
with the ligand, improving the interaction with the protein [20]. This difference in the 
dimension of the active-site gorge led us to implement a hydrated docking technique with the 
enzyme BChE [21]. 
When studying the binding mode and the interactions between these compounds and 
BChE, the best molecular docking conformation showed that compounds 2 and 9 penetrate the 
peripheral site through their A ring and bind the enzyme at the active site; both cases exhibit the 
triterpenoid buried deep into the gorge next to the residue SER198 (belonging to the catalytic 
triad), according to the competitive inhibition mechanism of the BChE that the in vitro 
experiments revealed.  
The study permitted us to identify hydrophobic interactions inside the gorge as well as 
three hydrogen bonding interactions as stabilizing factors in the enzyme-inhibitor complex for 
both compounds. The hydrophobic interactions are depicted in Figure 4. Due to both 
compounds sharing the same position at the gorge of the enzyme, the figure only represents 
these interactions between the BChE and compound 2. Regarding the hydrogen bonding, the 
carbonyl group at C-16 of compound 9 interacts with the hydroxyl group of THR 120 (2.30Å) 
and the carbonyl group of TRP82 (water mediated 2.05 and 2.27Å). Also, the hydroxyl group at 
C-3 in compound 9 is close to the carbonyl group of LEU286 (2.22Å) (Figure 5). Similarly, the 
carbonyl group at C-16 of 2 is involved in the same two hydrogen bonds as compound 9, with 
the hydroxyl group of THR120 (2.22Å) and TRP82 water mediated (2.05 and 2.12Å). There is 
another water-bridged H-bond network between the carbonyl at C-30 and the residue ASN289 
(2.05 and 2.40 Å). These interactions are shown in Figure 6. The importance of the carbonyl 




are involved in a hydrogen bond that strongly dock the compounds at the active site of the 
protein.  
On the other hand, the molecular docking with the AChE revealed that although both 
compounds get into the enzyme in the same way they penetrate the BChE (through their ring A), 
both compounds are located at the peripheral aromatic site of the enzyme, and the main 
interactions that stabilized these compounds are hydrophobic. Additionally, compound 2 
showed only one hydrogen bond between the carbonyl of C-30 and the NH of the amide group 
of PHE288.  
 
Figure 4. Hydrophobic interactions between compound 2 and the enzyme butyrylcholinesterase. 
 
 






Figure 6. Hydrogen bonds between compound 2 and the enzyme BChE. 
 
According to the results described for both compounds with the two cholinesterases, the 
stronger interaction between these triterpenoids and BChE is highlighted. This result clearly 
explains the molecular mechanism of the selectivity of these compounds toward the mentioned 
enzyme. 
The docking studies allowed us to establish the orientation of the inhibitors relative to 
the BChE, as well as its conformation when bound to the enzyme. This study permitted us to 
identify hydrophobic interactions inside the gorge as well as hydrogen bonding interactions as 
the stabilizing factors in the enzyme-inhibitor complex. Moreover, this work allowed us to 
understand the molecular basis of the selectivity of these compounds toward the enzyme BChE.  
Further molecular dynamics studies using this complex as the starting point are 
necessary to check the complex inhibitor-enzyme stability, to determinate if the enzyme 
undergoes structural rearrangements, and to verify the distances and angles observed in the 
interactions are within a suitable range.  
 
3. Conclusions 
Starting from calenduladiol (1) and lupeol (3), two natural triterpenoids, we have 




semisynthetic triterpenoids were obtained and fully characterized, together with seven known 
ones, in order to understand the influence of the carbonyl group in the interaction of these 
compounds with AChE and BChE. Compounds 2 and 9 were identified as the most effective 
BChE inhibitors. A kinetic study indicated that 2 and 9 are able to bind to the enzyme in a 
competitive manner. The experimental results were explained by means of molecular modeling, 
which helps to understand the selectivity of these inhibitors towards BChE. Also, this study 
allowed us to identify hydrophobic interactions inside the gorge, as well as hydrogen bonding 
interactions as the stabilizing factors in the enzyme-inhibitor complex. 
These results show that oxidation of C-16 is an efficient way to improve cholinesterase 
inhibition in this kind of inhibitor. Since compounds 2 and 9, the most active in the series, can 
be further modified in the isopropenyl attached to ring E, they appear to be good candidates to 
explore the scope of this scaffold as potential lead compounds in the search of new anti-
Alzheimer’s drugs. 
 
4. Experimental Section  
4.1 General 
Melting points were determined on a Fisher-Johns apparatus and are uncorrected. NMR 
measurements, including COSY, HSQC, HMBC experiments, were carried out on Bruker 
ARX300, Bruker Avance 400 and/or Bruker AMK 600 spectrometers. NMR spectra were 
recorded in CDCl3. Chemical shifts are given in ppm (δ) with TMS as an internal standard. 
Electrospray ionization mass spectra (ESI-MS) were recorded using an Esquire 3000 ion trap 
mass spectrometer equipped with a standard ESI/APCI source. UV spectra were recorded on a 
JASCO V-630BIO spectrophotometer. Elemental analyses (C, H) were performed with 
EXETER ANALYTICAL, INC CE-440 Elemental Analyzer. IR spectra were recorded on a 
Perkin-Elmer Paragon 1000 FT-IR spectrometer. 
Silica gel 60 (0.2–0.63 mm, Merck) was used for column chromatography. Silica gel 60 




on Silicagel 60 F254 sheets (0.2 mm thickness, Merck). p-Anisaldehyde-acetic acid spray 
reagent and UV light (254 and 366 nm) were used for detection. 
All chemicals and solvents were analytical grade and solvents were purified by general 
methods before being used. AChE from electric eel (type VI-S), 5,5 -dithiobis(2-nitrobenzoic 
acid) (DTNB), acetylthiocholine iodide (ATCI), butyrylthiocholine iodide (BTCI) and tacrine 
were purchased from Sigma. BChE (horse serum) was purchased from MP Biomedicals. 
Calenduladiol (1) and lupeol (3), used as starting materials for the preparation of compounds 2, 
4–13, were extracted from aerial parts of C. erinacea subsp. erinacea as previously described 
[8]. 
All derivatives were rigorously characterized by NMR spectroscopy and mass 
spectrometry. The NMR data of derivatives 2, 4–8 and 10 were identical to those previously 
reported [7, 11, 12, 17]. 
Compounds 9, 11–13 are described here for the first time and bidimensional NMR 
spectra (COSY, HMBC, HSQC) were used for the unequivocal assignments of all carbons and 
representative protons.  
 
4.2 Preparation of 3,16-dioxo-lup-20(29)-en-30-al (2) 
To a solution of 7 (50.0 mg, 0.11 mmol) in acetone (3 mL) Jones reagent was added 
dropwise at 0 °C until the solution changed remained orange. The reaction was stirred for 30 
min and quenched with i-PrOH (2 mL), filtered through Florisil and washed several times with 
AcOEt. The solvent was removed and the residue was purified by flash chromatography on 
silica gel with hexane/AcOEt (9:1) affording 12.9 mg (26%) of compound 2 as a white 
amorphous solid. Spectroscopic and spectrometric data of 2 were in agreement with those 
previously reported by our group [7]. 
1
H NMR (600 MHz, CDCl3)  0.89 (3H, s, H-27), 0.93 
(3H, s, H-25), 1.02 (3H, s, H-24), 1.07 (3H, s, H-28), 1.13 (6H, s, H-23, H-26), 2.48 (1H, ddd, J 
= 8.6, 15.7, 15.9 Hz, H-19), 2.74 (1H, d, J = 13.8 Hz, H-15a), 5.98 (1H, br s, H-29a), 6.29 (1H, 
br s, H-29b), 9.52 (1H, s, H-30); 
13
C NMR (150 MHz, CDCl3)  217.9 (C-3), 215.4 (C-16), 




14), 47.4 (C-4), 44.9 (C-15), 41.0 (C-8), 39.6 (C-1), 37.3 (C-13, C-19), 36.9 (C-10), 34.2 (C-2), 
33.6 (C-7, C-22), 31.3 (C-12, C-21), 26.8 (C-23), 21.2 (C-11), 21.2 (C-24), 19.6 (C-6), 18.1 (C-
28), 16.3 (C-26), 15.9 (C-25), 15.4 (C-27). 
 
4.3 Preparation of lup-20(29)-en-3-one (4) 
Compound 4 was prepared from 3 (50.0 mg, 0.12 mmol) following the same procedure 
described for the preparation of 2. The crude material was chromatographed over flash silica gel 
with hexane/AcOEt (9:1) to afford 47.4 mg (95%) of compound 4 as a white amorphous solid. 
Spectroscopic and spectrometric data of 4 were identical to those reported for lupenone [11, 12]. 
1
H NMR (300 MHz, CDCl3) δ 0.83 (3H, s, H-28), 0.85 (3H, s, H-25), 0.94 (3H, s, H-27), 0.96 
(3H, s, H-24), 1.03 (6H, s, H-23, H-26), 1.63-1.25 (27H, m), 2.41 (1H, m, H-19), 4.54 (1H, br s, 
H-29b), 4.67 (1H, br s, H-29a); 
13
C NMR (75 MHz, CDCl3) δ 218.0 (C-3), 150.8 (C-20), 109.5 
(C-29), 55.0 (C-5), 49.9 (C-9), 48.3 (C-18), 48.0 (C-19), 47.4 (C-4), 43.1 (C-17), 43.1 (C-14), 
40.9 (C-8), 40.1 (C-22), 39.7 (C-13), 38.2 (C-1), 36.9 (C-10), 35.7 (C-16), 34.2 (C-2), 33.7 (C-
7), 29.9 (C-21), 27.5 (C-15), 26.8 (C-23), 25.2 (C-12), 21.6 (C-24), 21.1 (C- 11), 19.8 (C-30), 
19.8 (C-6), 18.1 (C-28), 16.2 (C-26), 16.0 (C-25), 15.9 (C-27). 
 
4.4 Preparation of 3β-hydroxy-lup-20(29)-en-30-al (5) 
A solution of 3 (40.0 mg, 0.09 mmol) in EtOH (5 mL) was treated with SeO2 (24.2 mg, 
0.22 mmol). The reaction mixture was heated under reflux until the disappearance of the starting 
material was confirmed by TLC (24 h). Then, the reaction mixture was cooled and EtOH was 
removed under reduced pressure. The crude was treated with water (20 mL) and extracted with 
CH2Cl2 (3 x 30 mL). The combined organic extracts were dried over MgSO4, filtered, and 
concentrated under reduced pressure. The residue was purified by column flash chromatography 
on silica gel with hexane/AcOEt (7:3) to afford 18.0 mg (44%) of compound 5 as a white 
crystalline solid. Compound 5 showed identical spectroscopic and spectrometric data to those 
previously reported [16]. 
1
H NMR (300 MHz, CDCl3) δ 0.66 (1H, d, J = 9.0 Hz, H-5), 0.75 (3H, 




(3H, s, H-23), 1.30-1.19 (5H, m), 1.38 (4H, br s), 1.52-1.41 (5H, m), 1.55 (3H, br s), 1.70-1.60 
(5H, m), 2.15 (1H, t, J = 11.1 Hz, H-21a), 2.75 (1H, ddd, J = 10.9, 10.9, 5.6 Hz H-19), 3.17 
(1H, dd, J = 10.6, 5.3 Hz, H-3), 5.90 (1H, br s, H-29b), 6.28 (1H, br s, H-29a), 9.51 (1H, s, H-
30); 
13
C NMR (75 MHz, CDCl3) δ 195.2 (C-30), 157.4 (C-20), 133.3 (C-29), 79.1 (C-3), 55.4 
(C-5), 50.4 (C-9, C-18), 43.4 (C-17), 42.8 (C-14), 40.9 (C-8), 40.1 (C-22), 39.0 (C-4), 38.9 (C-
1), 37.9 (C-13), 37.3 (C-10, C-19), 35.5 (C-16), 34.4 (C-7), 28.1 (C-21, C-23), 27.5 (C-2, C-12), 
27.5 (C-15), 21.1 (C-11), 18.5 (C-6), 17.9 (C-28), 16.2 (C-25), 16.1 (C-26), 15.5 (C-24), 14.6 
(C-27). 
 
4.5 Preparation of 3-oxo-lup-20(29)-en-30-al (6) 
Compound 6 was prepared from 5 (15.0 mg, 0.03 mmol) following the same procedure 
described for the preparation of 2. The crude material was chromatographed over flash silica gel 
with hexane/AcOEt (9.5:0.5) to afford 7.9 mg (53%) of compound 6 as a white amorphous 
solid. Spectroscopic and spectrometric data of 6 were identical to those reported by Mutai et al 
[11]. 
1
H NMR (300 MHz, CDCl3) δ 0.83 (3H, s, H-28), 0.91 (3H, s, H-25), 0.93 (3H, s, H-27), 
1.02 (3H, s, H-24), 1.05 (3H, s, H-23), 1.06 (3H, s, H-26), 1.08 (2H, br s), 1.54-1.25 (15H, m), 
1.56 (2H, m), 1.76-1.62 (4H, m), 1.87 (1H, ddd, J = 13.2, 7.5, 4.4 Hz, H-1a), 2.50-2.37 (2H, m), 
2.76 (1H, ddd, J = 10.9, 10.7, 5.8 Hz, H-19), 5.91 (1H, br s, H-29b), 6.28 (1H, br s, H-29a), 
9.51 (1H, s, H-30); 
13
C NMR (75 MHz, CDCl3) δ 218.2 (C-3), 195.2 (C-30), 157.3 (C-20), 
133.3 (C-29), 55.1 (C-5), 49.8 (C-9, C-18), 47.5 (C-4), 43.4 (C-14), 42.9 (C-17), 40.9 (C-8), 
40.1 (C-22), 39.8 (C-1), 38.0 (C-13, C-19), 37.0 (C-10), 35.5 (C-16), 34.3 (C-2), 33.7 (C-7), 
27.5 (C-12, C-15), 26.7 (C-21, C-23), 21.6 (C-11), 21.2 (C-24), 19.8 (C-6), 17.9 (C-28), 16.0 
(C-25), 15.9 (C-26), 14.5 (C-27). 
 
4.7 Preparation of 3β,16β-dihydroxy-lup-20(29)-en-30-al (7) 
Compound 7 was prepared from 1 (60.0 mg, 0.14 mmol) following the same procedure 
described for the preparation of 5. The crude material was chromatographed over flash silica gel 




Spectroscopic and spectrometric data of 7 were in agreement with those previously reported by 
our group [7]. 
1
H NMR (300 MHz, CDCl3) δ 0.74 (3H, s, H-24), 0.79 (3H, s, H-28), 0.81 (3H, s, 
H-26), 0.95 (3H, s, H-25), 0.95 (3H, s, H-27), 1.00 (3H, s, H-23), 2.85 (1H, ddd, J = 5.7, 10.5, 
10.8 Hz, H-19), 3.15 (1H, dd, J = 5.1, 10.5 Hz, H-3), 3.66 (1H, dd, J = 4.8, 11.1 Hz, H-16), 5.91 
(1H, br s, H-29a), 6.27 (1H, br s, H-29b), 9.5 (1H, s, H-30); 
13
C NMR (75 MHz, CDCl3) δ 195.0 
(C-30), 156.4 (C-20), 133.5 (C-29), 79.0 (C-3), 77.0 (C-16), 55.4 (C-5), 49.9 (C-9, C-18), 48.9 
(C-17), 44.0 (C-14), 41.0 (C-8), 39.0 (C-4), 38.8 (C-1), 37.8 (C-22), 37.2 (C-10), 37.1 (C-13, C-
19), 37.0 (C-15), 34.3 (C-7), 29.8 (C-21), 28.1 (C-23), 27.4 (C-2), 27.2 (C-12), 21.0 (C-11), 
18.4 (C-6), 16.2 (C-26), 16.1 (C-25, C-27), 15.5 (C-24), 11.7 (C-28). 
 
4.8 Preparation of 3,16-dioxo-lup-20(29)-ene (8) 
Compound 8 was prepared from 1 (50.0 mg, 0.11 mmol) following the same procedure 
described for the preparation of 2. The crude material was chromatographed over flash silica gel 
with hexane/AcOEt (9:1) to afford 20.8 mg (42%) of compound 8 as a white amorphous solid. 
Spectroscopic and spectrometric data of 8 were in agreement with those previously reported by 
our group [7].
 1
H NMR (400 MHz, CDCl3)  0.90 (3H, s, H-27), 0.93 (3H, s, H-25), 1.01 (3H, s, 
H-24), 1.06 (3H, s, H-23), 1.09 (3H, s, H-28), 1.14 (3H, s, H-26), 1.65 (3H, s, H-30), 2.61 (1H, 
ddd, J = 6.3, 10.8, 10.9 Hz, H-19), 2.71 (1H, d, J = 13.6 Hz, H-15a), 4.62 (1H, br s, H-29a), 
4.73 (1H, br s, H-29b); 
13
C NMR (100 MHz, CDCl3)  217.8 (C-3), 215.8 (C16), 148.8 (C-20), 
110.8 (C-29), 56.7 (C-17), 54.8 (C-5), 49.4 (C-9), 49.4 (C-18), 48.1 (C-14), 47.4 (C-4, C-19), 
44.9 (C-15), 41.0 (C-8), 39.6 (C-1), 37.7 (C-13), 36.9 (C-10), 34.1 (C-2), 33.6 (C-7), 31.2 (C-
22), 28.6 (C-21), 26.8 (C-23), 24.8 (C-12), 21.3 (C-11), 21.1 (C-24), 19.7 (C-6), 19.0 (C-30), 
18.1 (C-28), 16.3 (C-26), 16.0 (C-25), 15.4 (C-27). 
 
4.9 Preparation of 3β-hydroxy-lup-20(29)-en-16-one (9) and 16β-hydroxy-lup-20(29)-en-3-one 
(10) 
Compounds 9 and 10 were prepared from 1 (50.0 mg, 0.11 mmol) following the 




dropwise at 0 °C until the appearance of the ketones 9 and 10 was confirmed by TLC, and there 
was no evidence of the presence of diketone 8. The crude material was chromatographed over 
flash silica gel with hexane/AcOEt (9.3:0.7) to afford 8.7 mg (17%) of compound 9 and 7.6 mg 
(15%) of compound 10 as white amorphous solids. 
Compound 9: 
1
H NMR (300 MHz, CDCl3) δ 0.68 (1H, d, J = 9.5 Hz, H-5), 0.77 (3H, s, 
H-24), 0.85 (3H, s, H-25), 0.90 (3H, s, H-27), 0.97 (3H, s, H-23), 1.10 (3H, s, H-28), 1.11 (3H, 
s, H-26), 1.44-1.36 (8H, m), 1.61- 1.54 (9H, m), 1.66 (3H, s, H-30), 1.83-1.86 (3H, m), 2.12 
(1H, ddd, J = 12.5, 12.0, 4.1 Hz, H-13), 2.61 (1H, ddd, J = 11.3, 10.9, 6.0 Hz, H-19), 2.71 (1H, 
d, J = 13.9 Hz, H-15a), 3.19 (1 H, dd, J = 10.9, 5.2 Hz, H-3), 4.63 (1H, br s, H-29b), 4.74 (1H, 
br s, H-29a); 
13
C NMR (75 MHz, CDCl3) δ 216.1 (C-16), 148.9 (C-20), 110.8 (C-29), 79.0 (C-
3), 56.7 (C-5), 55.3 (C-17), 50.1 (C-9), 49.6 (C-18), 48.2 (C-14), 47.5 (C-19), 45.0 (C-15), 41.2 
(C-8), 39.0 (C-1), 38.9 (C-4), 37.6 (C- 13), 37.3 (C-10), 34.3 (C-7), 31.3 (C-22), 28.7 (C-21), 
28.1 (C-23), 27.5 (C-2), 24.8 (C-12), 20.8 (C-11), 19.1 (C-30), 18.4 (C-6), 18.1 (C-28), 16.6 (C-
26), 16.1 (C-25), 15.5 (C-24), 15.5 (C-27); MS (ESI, positive ions), m/z 441.4 [M+H]
+
. Anal. 
Calcd. for C30H48O2: C 81.76; H 10.98. Found: C 81.81; H 11.03.  
Compound 10: 
1
H NMR (300 MHz, CDCl3) δ 0.80 (3H, s, H-28), 0.93 (3H, s, H-26), 
1.00 (3H, s, H-25), 1.02 (3H, s, H-24), 1.07 (6H, s, H-23, H-27), 1.68 (3H, s, H-30), 1.53-1.26 
(17H, m), 2.04-1.89 (3H, m), 2.50-2.42 (3H, m), 3.61 (1H, dd, J = 10.6, 4.7 Hz, H-16), 4.60 
(1H, br s, H-29b), 4.71 (1H, br s, H-29a); 
13
C NMR (75 MHz, CDCl3) δ 218.2 (C-3), 150.0 (C-
20), 110.0 (C- 29), 77.2 (C-16), 55.1 (C-5), 49.5 (C-9), 48.8 (C-17), 47.8 (C-18), 47.7 (C- 19), 
47.5 (C-4), 44.3 (C-14), 41.0 (C-8), 39.8 (C-1), 37.8 (C-22), 37.5 (C-13), 37.0 (C-10), 37.0 (C-
15), 34.2 (C-2), 33.7 (C-7), 30.0 (C-21), 26.8 (C-23), 24.9 (C-12), 21.5 (C-11), 21.2 (C-24), 
19.8 (C-6), 19.5 (C-30), 16.2 (C-25), 16.1 (C-27), 15.9 (C-26), 11.8 (C-28); MS (ESI, positive 
ions), m/z 463.4 [M+Na]
+
. Anal. Calcd. for C30H48O2: C 81.76; H 10.98. Found: C 81.82; H 
11.01. 
 




Compound 11 was prepared from 9 (14.0 mg, 0.03 mmol) following the same procedure 
described for the preparation of 5. The crude material was chromatographed over flash silica gel 
with hexane/AcOEt (7:3) to afford 6.8 mg (47%) of compound 11 as a white amorphous solid. 
1
H NMR (300 MHz, CDCl3) δ 0.66 (1H, d, J = 10,2 Hz, H-5), 0.76 (3H, s, H-24), 0.83 (3H, s, 
H-25), 0.88 (3H, s, H-27), 0.97 (3H, s, H-23), 1.09 (3H, s, H-28), 1.13 (3H, s, H-26), 1.26 (3H, 
s), 1.44-1.34 (4H, m), 1.73-1.45 (8H, m), 1.82 (1H, d, J = 14.4 Hz, H-15b), 2.06-1.87 (2H, m), 
2.17- 2.08 (2H, m), 2.73 (1H, d, J = 13.8 Hz, H-15a), 2.99 (1H, ddd, J = 10.9, 10.8, 6.0 Hz, H-
19), 3.17 (1H, dd, J = 10.6, 4.9 Hz, H-3), 5.97 (1H, br s, H-29b), 6.28 (1H, br s, H-29a), 9.52 
(1H, s, H-30); 
13
C NMR (75 MHz, CDCl3) δ 215.5 (C-16), 194.7 (C-30), 156.5 (C-20), 132.4 
(C-29), 79.0 (C-3), 56.9 (C-5), 55.3 (C-17), 49.9 (C-9, C-18), 47.8 (C-14), 45.0 (C-15), 41.1 (C-
8), 39.0 (C-1), 38.8 (C-4), 37.3 (C-13), 37.2 (C-10, C-19), 34.3 (C-7), 31.3 (C-22), 29.8 (C-21), 
28.1 (C-23), 27.5 (C-2), 27.1 (C-12), 20.8 (C-11), 18.3 (C- 6), 18.0 (C-28), 16.5 (C-26), 16.1 
(C-25), 15.5 (C-24), 15.4 (C-27); MS (ESI, positive ions), m/z 477.4 [M+Na]
+
. Anal. Calcd. for 
C30H46O3: C 79.25; H 10.20. Found: C 79.28; H 10.23. 
 
4.11 Preparation of 16β-hydroxy-3-oxo-lup-20(29)-en-30-al (12) and 16β-hydroxy-3-oxo-lup-
1,20(29)-dien-30-al (13) 
Compound 12 and 13 were prepared from 10 (7.8 mg, 0.02 mmol) following the same 
procedure described for the preparation of 5. The crude material was chromatographed over 
flash silica gel with hexane/AcOEt (8.5:1.5/8.3:1.7) to afford 1.1 mg (14%) of compound 12 
and 1.5 mg (19%) of compound 13.  
Compound 12: 
1
H NMR (300 MHz, CDCl3) δ 0.83 (3H, s, H-28), 0.92 (3H, s, H-26), 
0.98 (3H, s, H-25), 1.02 (3H, s, H-27), 1.06 (3H, s, H-24), 1.07 (3H, s, H-23), 1.74-1.26 (20H, 
m), 2.47-2.40 (2H, m, H-2), 2.86 (1H, ddd, J = 10.8, 10.5, 5.7 Hz, H-19), 3.69 (1H, dd, J = 11.2, 
4.8 Hz, H-16), 5.93 (1H, br s, H-29b), 6.29 (1H, br s, H-29a), 9.52 (1H, s, H-30); 
13
C NMR (75 
MHz, CDCl3) δ 217.9 (C-3), 195.0 (C-30), 156.9 (C-20), 133.0 (C-29), 76.9 (C-16), 53.5 (C-5), 
49.2 (C-9, C-17, C-18), 44.8 (C-4), 44.1 (C-14), 41.9 (C-8), 39.7 (C-1), 37.9 (C-22), 37.1 (C-13, 




21.3 (C-11), 21.1 (C-24), 19.7 (C-6), 16.0 (C-25), 15.8 (C-27), 15.8 (C-26), 11.7 (C-28); MS 
(ESI, positive ions), m/z 455.4 [M+H]
+
. Anal. Calcd. for C30H46O3: C 79.25; H 10.20. Found: C 
79.30; H 10.24. 
Compound 13: 
1
H NMR (300 MHz, CDCl3) δ 0.85 (3H, s, H- 28), 0.96 (3H, s, H-27), 
1.05 (3H, s, H-25), 1.08 (3H, s, H-24), 1.10 (3H, s, H-26), 1.13 (3H, s, H-23), 2.00-1.26 (16H, 
m), 2.94-2.82 (1H, m, H-19), 3.69 (1H, dd, J = 11.2, 4.8 Hz, H-16), 5.78 (1H, d, J = 10.2 Hz, H-
2), 5.95 (1H, br s, H-29b), 6.30 (1H, br s, H-29a), 7.05 (1H, d, J = 10.2 Hz, H-1), 9.53 (1H, s, 
H-30); 
13
C NMR (75 Hz, CDCl3) δ 205.5 (C-3), 195.0 (C-30), 159.5 (C-1), 156.2 (C-20), 133.5 
(C-29), 125.4 (C-2), 76.9 (C-16), 53.6 (C-5), 49.0 (C-17, C-18), 44.8 (C-4), 44.2 (C-9), 44.1 (C-
14), 41.9 (C-8), 39.6 (C-10), 37.9 (C-22), 37.3 (C-13, C-19), 36.9 (C-15), 33.9 (C-7), 31.7 (C-
21), 27.9 (C-23), 27.1 (C-12), 21.5 (C-24), 21.3 (C-11), 19.3 (C-25), 19.1 (C-6), 16.6 (C-26), 
14.3 (C-27), 11.8 (C-28); MS (ESI, positive ions), m/z 453.4 [M+H]
+
. Anal. Calcd. for 
C30H44O3: C 79.60; H 9.80. Found: C 79.64; H 9.85. 
 
4.12 Inhibition assay on AChE and BChE in vitro  
Electric eel (Torpedo californica) AChE and horse serum BChE were used as source of 
both the cholinesterases. AChE and BChE inhibiting activities were measured in vitro by the 
spectrophotometric method developed by Ellman with slight modification [19]. The lyophilized 
enzyme, 500U AChE/300U BChE, was prepared in buffer A (8 mM K2HPO4, 2.3 mM 
NaH2PO4) to obtain 5/3 U/mL stock solution. Further enzyme dilution was carried out with 
buffer B (8mM K2HPO4, 2.3 mM NaH2PO4, 0.15 M NaCl, 0.05% Tween 20, pH 7.6) to produce 
0.126/0.06 U/mL enzyme solution. Samples were dissolved in buffer B with 2.5% of MeOH as 
cosolvent. Enzyme solution (300 μL) and sample solution (300 μL) were mixed in a test tube 
and incubated for 60/120 min at room temperature. The reaction was started by adding 600 μL 
of the substrate solution (0.5 mM DTNB, 0.6 mM ATCI/BTCI, 0.1 M Na2HPO4, pH 7.5). The 
absorbance was read at 405 nm for 180 s at 27ºC. Enzyme activity was calculated by comparing 




values were determined with GraphPad Prism 5. Tacrine (99%) was used as reference 
AChE/BChE inhibitor. 
 
4.13 Kinetic characterization of BChE inhibition 
The enzyme reaction was carried out at three fixed inhibitor concentrations (0, 20 and 
70 μM for compound 2; 0, 10 and 75 μM for compound 9). In each case the initial velocity 
measurements were obtained at varying substrate (S) (butyrylthiocholine) concentrations and 
the reciprocal of the initial velocity (1/v) was plotted as a function of the reciprocal of [S] 
(1/[S]). The double-reciprocal (Lineweaver–Burk) plot showed a pattern of intersecting lines 
with increasing slopes, characteristic of a competitive inhibitor. The data of the enzyme activity 
at different fixed substrate concentrations with increasing inhibitor concentrations were 
analyzed with GraphPad Prism 5. The nonlinear regression of these data fitted with competitive 
inhibition with R
2
= 0.9836 for 2 and R
2
= 0.9802 for 9. The calculated Ki were 51.16 μM for 9 
and 32.70 μM for 2.  
 
4.14 Molecular docking determinations  
Human BChE crystal structure 1P0I [22] and Torpedo californica AChE crystal 2ACE 
[23] were used for the docking simulations of compounds 2 and 9. Due to both compounds are 
competitive inhibitors, the acetylcholine was not present at their active site. Geometry 
optimization of the compounds was performed with semiempirical calculations (AM1) and the 
Hartree-Fock method and the 6-31G (d, p) basis set incorporated in the Gaussian 03 program 
[24-26]. Docking studies were performed with version 4.2.5.1 of the program AutoDock, using 
the implemented empirical free energy function [21, 27]. The graphical user interface program 
AutoDock Tools was used to prepare, run and analyze the docking simulations. The simulation 
space was defined as box which included the active site and the peripheral site. Atomic 
interaction energy on a 0.375 Å grid was calculated with the auxiliary program Autogrid 4 using 




compounds were allowed to rotate freely. The starting position of the triterpene was outside the 
grid on a random position. 
The triterpenes were docked by the Lamarckian genetic algorithm protocol. A total of 
256 independent simulations with a population size of 150 members were run for each 
compound using AutoDock 4.2.5.1 with default parameters (random starting position and 
conformation, translation step of 2.0 Å, mutation rate of 0.02, crossover rate of 0.8, local search 
rate 0.06 and 2500000 energy evaluations). After docking, the 256 conformers generated for the 
inhibitors were assigned to clusters based on a tolerance of 2.0 Å all atom root-mean-square 
deviation (rmsd) in position from the lowest-energy solution. The clusters were also ranked 
according to the energies of their representative conformations, which were the lowest-energy 
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 A set of mono-, di- and tri-oxolupanes were prepared starting from calenduladiol and 
lupeol. 
 Selective inhibition of butyrylcholinesterase was observed for all the derivatives.  
 Kinetic study and molecular modeling were carried with the most potent inhibitors. 
 Oxidation at C-16 of the lupane skeleton improves the cholinesterase inhibition. 
 
